Floatz logo

Gilteritinib

Sorafenib

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Sorafenib cohort.

Asset / SponsorPhaseRating
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 4BBB
Ethiodized Oil
Sun Yat-sen University
Phase 3B
Theprubicin
Sun Yat-sen University
Phase 3B
Inno-206
Sun Yat-sen University
Phase 3B
Toripalimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3B
Gefetinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
D

Same molecule, other indications

Gilteritinib is also rated in:

acute myeloid leukemia, FLT3 internal tandem duplicationDormant
BB
Indicative ·
69 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →